As Pfizer begins human trials, CBER’s Marks eyes nine-month target for a vaccine and urges at-risk manufacturing once a candidate reaches Phase III.
The development of a COVID-19 vaccine potentially could take as little as nine months by removing the “dead space” in the development process and manufacturing at risk, the US Food and Drug Administration’s Peter Marks said during an Axios webinar on 4 May.
US government scientists and politicians have suggested a vaccine against the novel coronavirus could be available within 12-18 months, an...
Stefan Oelrich, the newly-announced president of European pharma industry federation EFPIA says the EU pharma reform is “not an improvement on the status quo” in its current form.
Oncology trial sponsors in the UK are being invited to participate in a pilot that aims to tackle duplication and variation in pharmacy reviews, which are an important part of setting up clinical trials in the National Health Service.
The new Advisory Committee on Immunization Practices voted for new recommendations on the decades-old thimerosal safety issue and lays intellectual groundwork to revisit other past controversies and decisions.
